Sangeetha Raghuraman, MD
Addiction Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raghuraman’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A78175 · Current
Licensed to practise in California · since 2002 · expires 2027-06-30 · Dr. M. G. R. Medical University, Madras Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Drugs they prescribed that Part D paid
$3,284
Pharmacies billed $3,284 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 50) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
50 generic and 0 brand-name prescriptions · $3,284 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Buprenorphine-Naloxone | 50 | $3,284 | $66 |
Year by year
| 2024 | 50 | None | 0% (0) | 0% | $3,284 |
| 2023 | 50 | None | 0% (0) | 0% | $8,937 |
| 2022 | 63 | None | 0% (0) | 21% | $17,310 |
| 2021 | 40 | None | 0% (0) | None | $6,766 |
| 2020 | 32 | None | 0% (0) | 0% | $3,223 |
| 2019 | 28 | None | 0% (0) | 0% | $5,006 |
| 2018 | 28 | None | 0% (0) | None | $5,723 |
| 2017 | 28 | None | 0% (0) | 93% | $8,353 |
| 2016 | 41 | None | 0% (0) | 68% | $9,296 |
| 2015 | 51 | None | 0% (0) | 25% | $5,662 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Buprenorphine-Naloxone | 50 | $8,937 | $179 |
2022: 2 drugs
| Zubsolv | 13 | $10,067 | $774 |
| Buprenorphine-Naloxone | 50 | $7,244 | $145 |
2021: 1 drug
| Buprenorphine-Naloxone | 37 | $5,163 | $140 |
2020: 1 drug
| Buprenorphine-Naloxone | 30 | $3,116 | $104 |
2019: 1 drug
| Buprenorphine-Naloxone | 28 | $5,006 | $179 |
2018: 1 drug
| Buprenorphine-Naloxone | 22 | $3,755 | $171 |
2017: 1 drug
| Suboxone | 26 | $8,260 | $318 |
2016: 2 drugs
| Suboxone | 26 | $7,110 | $273 |
| Buprenorphine-Naloxone | 13 | $1,333 | $103 |
2015: 2 drugs
| Buprenorphine-Naloxone | 38 | $3,674 | $97 |
| Suboxone | 11 | $1,203 | $109 |
Money from drug and device companies
$119 in 2025
A payment is not proof that care is biased.
| Braeburn | Brixadi | $119 | 1 payment
|
See the published payment
| Braeburn | Meals · 2025-08-14 | Brixadi | $119 |
Professional record
- NPI
- 1396814356
- Licence
- CA A78175California A78175: Current · expires 2027-06-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RA0401X (207RA0401X); Internal medicine (207R00000X)
- Mailing address
- 751 S Bascom Ave, San Jose, CA, 95128
- NPI first listed
- 2006-11-06
- NPI last updated
- 2007-09-12
This is when the NPI record was last certified, not a medical board exam.